Lupin receives US FDA approval for Cefprozil Tablets

BSE: 500257	NSE: LUPIN	REUTERS: LUPN.BO	BLOOMBERG: LPC IN

Mumbai, December 9, 2005: Lupin Ltd. today announced that it has received US FDA approval for its Abbreviated New Drug Application (ANDA) for Cefprozil Tablets USP, 250 mg and 500 mg. Cefprozil is the generic equivalent of Bristol Myers Squibb's Cefzil®. The tablet market in the US is USD 117 million as per IMS MAT June 2005 data.

Speaking of the approval, Chairman Dr. D B Gupta said: "We are delighted with the approval of Cefprozil Tablets and look forward to launching the product post patent expiry on Dec. 23rd 2005, and gaining a profitable market share. The expeditious review and approval by the US FDA is a sign of their confidence in Lupin and the quality of our filings."

This is Lupin's ninth ANDA approval by the US FDA till date and the fourth in this financial year.

About Lupin

Headquartered in Mumbai, Lupin (http:/www.lupinworld.com) develops, manufactures and markets generic intermediates, active pharmaceutical ingredients and finished dosages. Its FY 2004-05 revenues were Rs.12 billion. 11 of Lupin's plant have been approved by the US FDA and two facilities have been approved by the UK MHRA

For further information contact:
Raju Kane
The Source
Mobile: +91 98200 45656
E-mail: **rajukane@sourcepr.com**